Adjuvant chemotherapy with pemetrexed and

Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and

cisplatin: the TREAT protocol. BMC Cancer 2007, 7:77.PubMedCrossRef 14. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008, 26:3543–3551.PubMedCrossRef 15. Ricciardi S, Tomao S, de Marinis F: Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag 2009, 5:781–787.PubMed 16. Scagliotti G, Hanna N, Fossella F, Sugarman K, Selleck Autophagy inhibitor Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253–263.PubMedCrossRef Selleck OICR-9429 17. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer

2009,66(2):141–149.PubMedCrossRef 18. Stinchcombe TE, Akt inhibitor Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009,6(2):233–241.PubMedCrossRef 19. Stinchcombe TE, Socinski MA: Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008,13(Suppl 1):28–36.PubMedCrossRef 20. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA: Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007,55(2):187–194.PubMedCrossRef 21. Shepherd FA, Dancey J, Arnold A, Neville

A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung Cytidine deaminase carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001,92(3):595–600.PubMedCrossRef 22. Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S: A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2008,110(2):309–315.PubMedCrossRef 23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000,92(3):205–216.PubMedCrossRef 24. Investigator’s handbook: a manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment National Cancer Institute [http://​ctep.​cancer.​gov/​investigatorReso​urces/​investigators_​handbook.​htm] 25.

Comments are closed.